Epcoritamab LBCL: Durable Response Analysis
- Patients with large B-cell lymphoma (LBCL) who achieved complete remission (CR) after two years of treatment with epcoritamab were more likely to exhibit lower tumor burden at the...
- the study, presented at the American Society of Clinical Oncology (ASCO) annual meeting, indicated that those with a CR at two years also had lower baseline ferritin levels...
- Epcoritamab,a bispecific T-cell engager targeting CD20 and CD3,is FDA-approved for follicular lymphoma (FL) patients who have undergone at least two prior systemic therapies.
The latest analysis reveals epcoritamab’s promising efficacy in treating large B-cell lymphoma (LBCL). Patients achieving complete remission at two years exhibited a lower tumor burden and reduced ferritin levels, according to findings from the EPCORE-NHL-1 trial. This study, presented at the ASCO annual meeting, underscores epcoritamab’s potential as a valuable treatment option. The research, covering 157 LBCL patients, indicates a median complete remission of 36 months. Explore the detailed outcomes and understand how epcoritamab, a bispecific T-cell engager, offers durable responses for LBCL patients, improving their overall survival. News Directory 3 delivers this critical data. Discover what’s next in lymphoma treatment developments.
Epcoritamab Shows Promise in Lymphoma Treatment, Study finds
Updated June 15, 2025
Patients with large B-cell lymphoma (LBCL) who achieved complete remission (CR) after two years of treatment with epcoritamab were more likely to exhibit lower tumor burden at the start of the treatment and reduced baseline ferritin levels. Thes findings come from a recent analysis of data derived from the phase 2 EPCORE-NHL-1 trial.
the study, presented at the American Society of Clinical Oncology (ASCO) annual meeting, indicated that those with a CR at two years also had lower baseline ferritin levels compared to those without.Prior CAR-T cell therapy use was similar in both groups.
Epcoritamab,a bispecific T-cell engager targeting CD20 and CD3,is FDA-approved for follicular lymphoma (FL) patients who have undergone at least two prior systemic therapies. This approval stemmed from the EPCORE-NHL-1 trial results,which were published in lancet Haematology. An expansion cohort study showed durable CRs across broader LBCL types.
The ASCO abstract highlighted long-term outcomes from a post-hoc analysis involving 157 LBCL patients in the EPCORE-NHL-1 trial. Epcoritamab was administered in 28-day cycles, starting with step-up doses of 0.16 mg and 0.8 mg, escalating to a full dose of 48 mg. This full dose was given weekly for the first three cycles, bi-weekly for cycles four through nine, and then every four weeks until disease progression or unacceptable toxicity.
After a three-year follow-up, epcoritamab monotherapy resulted in a median CR of 36 months and a median progression-free survival (PFS) of 37 months. The overall survival (OS) rate was not reached for patients with CR.
The post-hoc analysis compared characteristics of patients achieving CR at the two-year mark against those who did not. The primary endpoint was the overall response rate (ORR). As of May 3, 2024, 41% (65 patients) achieved CR, with 32 (49%) maintaining it at two years. This group had an average age of 63, with 47% being male, and 66% refractory to at least two prior therapies.
- 19% of those with a CR at 2 years had lower tumor burden at baseline, compared with 34%